Period Ending Dec 30, 2012 Dec 30, 2011 Dec 30, 2010
Total Revenue 7,328 5,320 3,708
Cost of Revenue 3,975 3,502 2,797
Gross Profit 3,353 1,818 911
Revenue up YOY. Gross profit doubling YOY. That is not BS, just facts. Yes COR is up YOY, but that was my point, which one will win out. See you in December sour #$%$.
They released 5/20. Erroneously got the E suffix on the stock due to the fact that they recalibrated when their fiscal year ended and FINRA mistakenly thought they were overdue. In any event the E suffix will be gone Tuesday and they reported 34% gain from previous year and went cash flow positive for the first time with latest release.
Sentiment: Strong Buy
This is the new normal, run the price up into earnings and then sell off and begin process again a few weeks later. What the company's numbers actually are rarely make a difference unless it is heavily shorted and numbers are inordinately good, such as NFLX. Design wins are fine but the real catalyst will be when NEON goes cash flow positive. Until then it will probably be heavily manipulated. Just buy the dips if you believe in the company and you will be fine long term.
Volume is not THAT heavy, projecting to about 40% above 90 day avg. so far. It has slowed markedly since the surge after 1:00 pm which tells me that a large position was liquidated and not a mass exodus. Nothing to see here until the royalties are spoken to by the judge or MSFT or ZTE breaks. Until then it's all just noise, including the USPTO news and today's subsequent dip in the share price.
This stock definitely marches to a different drummer. Low volume, high volatility. Kinda odd when one considers what a game changer Trovagene represents in regards to savings the healthcare industry will reap when their technology transplants the existing diagnostic tools.
Ha-ha. Why all the thumbs down action? I guess all of you are so ecstatic that you have to wait another 4-6 weeks to hear how it's going with the FDA that you view my irony as criticism of your tunnel visioned allegiance. And one thing you absolutely cannot entertain is more bad news from the FDA. What if that happens in June? I'll tell you what. Sub 2.00 will look damn good is what.
Contanely? Really? I generally do not make fun of people for their spelling errors but could not help myself this time mainly because you presume to tell me what to do with my money but can't spell continually. I assume you meant continually but there is no guarantee, plus no spell checker in the title bar of the post so you had to resort to hooked on phonics. Next time just google it.
I suppose we'll be back where we started from this morning soon enough. Unless of course the honorable Judge Raymond Alvin Jackson decides to make a move before or after the close. heh-heh, wouldn't that be something, watching 17 million shorts scrambling for cover.
No coincidence. PKI missed by 12% on their quarterly report. Has nothing to do with TROV, except that they are searching for new revenue. Or did you miss that?
Notice that ERFB now has 7.7 million outstanding instead of the 4.4 I thought they had. When did they dilute? Or did I read confuse the 4.4 million. Also, anyone else notice all the recent Form 4's from .58-.97/share?